Stupp regimen
2005
Radiotherapy + Concomitant and Maintenance Temozolomide for Glioblastoma
In 573 patients with newly diagnosed glioblastoma, radiotherapy + concurrent and maintenance temozolomide improved overall survival compared with radiotherapy alone.
Result
Efficacy: Overall survivalHR 0.63
Below 1 favours radiotherapy + concurrent and maintenance temozolomide, above 1 favours radiotherapy alone.
Event rates Radiotherapy + concurrent and maintenance temozolomide 14.6 vs radiotherapy alone 12.1 months
Also reported: 2-yr OS 26.5% vs 10.4%; 5-yr OS 9.8% vs 1.9%. MGMT-methylated subgroup: OS 21.7 vs 15.3 months.
- Subtopic
- Newly diagnosed GBM
- Design
- Open-label RCT
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Stupp R, et al. N Engl J Med. 2005;352(10):987-996; Stupp R, et al. Lancet Oncol. 2009;10(5):459-466.doi 10.1056/NEJMoa043330
Discussion & critique
Remains the backbone of GBM therapy two decades later. MGMT methylation is the defining predictive biomarker; tumour-treating fields (EF-14) is the only later addition with class-I evidence.